The company said that it expected its revenues to decline in 2017 as several of its products lose their exclusivity and generic competitors enter the market. (fortune.com)
AstraZeneca's upset stomach: AstraZeneca delayed entry of generic competitors of its anti-ulcer drug and prevented parallel trade by abusing patents and marketing procedures, the European Court of Justice held in reducing AstraZeneca's fine slightly, to $ 52.5 million from $ 60 million. (thelitigator.ca)
Often it turns out that the price increases by Valeant and Turing that have provoked the most criticism have been on drugs that are off - patent — meaning generic competitors are free to enter the market, typically bringing the price that most people pay for the drugs way down. (fortune.com)